Over 2 million Americans suffer from chronic inflammatory bowel disease (IBD) which includes Crohn’s disease and Ulcerative colitis [1, 2]. These patients experience debilitating digestive symptoms like persistent diarrhea, rectal bleeding, and abdominal pain resulting in a detrimental impact on quality of life. While the exact cause of IBD is not fully understood, there is […]
Rifaximin, a non-systemic antibiotic, is the standard of care for addressing SIBO [1]. However, it doesn’t work in over 50% of the patients [2]. The fortunate ones get their symptoms reduced but are rarely cured [3]. Further, 64% of the patients who benefit from Rifaximin relapse within a few months [4]. Clearly, a better solution […]
An estimated 700 million patients worldwide suffer from IBS. At Gutbiotics, our mission is to end IBS. We are developing genetically engineered bacteria that release antimicrobial peptides in the intestines and eliminate the IBS causing pathogens. In addition, the genetically engineered bacteria promote a healthy intestinal environment due to their probiotic nature. We are seeking […]
We sat down with Abigail Dancause – a competent healthcare professional who has been battling SIBO for the last seven years. Here are some of the things that jumped out: Listen to the entire discussion below
Dr. Bryan Davies is one of the leading researchers in the field of antimicrobial discovery and development. We had an insightful discussion with him on the future of anti-microbials for SIBO. Here are the highlights:
An estimated 700 million people are adversely affected by irritable bowel syndrome (IBS), that is one out of every ten people in the world. While IBS is not a life-threatening disease, it has a significant impact on quality of life. Small Intestine Bacterial Overgrowth (SIBO) is implicated in majority of the cases of irritable bowel […]